These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 6774537)
61. Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration. Rite I; Argüelles S; Venero JL; García-Rodriguez S; Ayala A; Cano J; Machado A J Neurosci Res; 2007 Dec; 85(16):3607-18. PubMed ID: 17705290 [TBL] [Abstract][Full Text] [Related]
62. [Biochemistry of the extrapyramidal system--from anatomical viewpoint]. Sano Y; Murase Y Shinkei Kenkyu No Shimpo; 1968 Dec; 12(4):859-68. PubMed ID: 4898006 [No Abstract] [Full Text] [Related]
63. Stereotactic treatment of action myoclonus in a case of combined status marmoratus and multiple sclerosis. A contribution to the pathophysiology of basal ganglia with multiple lesions in both the striatum and the substantia nigra. Hassler R; Schmidt K; Riechert T; Mundinger F Confin Neurol; 1975; 37(4):329-56. PubMed ID: 1097175 [TBL] [Abstract][Full Text] [Related]
64. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat. González-Hernández T; Barroso-Chinea P; Rodríguez M Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592 [TBL] [Abstract][Full Text] [Related]
65. Presynaptic regulation of neurotransmitter release in the brain: facts and hypothesis. Chesselet MF Neuroscience; 1984 Jun; 12(2):347-75. PubMed ID: 6146946 [No Abstract] [Full Text] [Related]
66. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms. Hornykiewicz O Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131 [No Abstract] [Full Text] [Related]
67. [Symposium on diseases of the basal ganglia. Nature of dystonia. I]. Denny-Brown D Rev Bras Med; 1968 Nov; 25(11):769-73 contd. PubMed ID: 5720951 [No Abstract] [Full Text] [Related]
68. Divergent regulatory mechanisms governing BDNF mRNA expression in cerebral cortex and substantia nigra in response to striatal target ablation. Rite I; Machado A; Cano J; Venero JL Exp Neurol; 2005 Mar; 192(1):142-55. PubMed ID: 15698628 [TBL] [Abstract][Full Text] [Related]
69. Neuroprotective mechanism of modafinil on Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Xiao YL; Fu JM; Dong Z; Yang JQ; Zeng FX; Zhu LX; He BC Acta Pharmacol Sin; 2004 Mar; 25(3):301-5. PubMed ID: 15000882 [TBL] [Abstract][Full Text] [Related]
70. On the intracerebral origin of homovanillic acid of the cerebrospinal fluid of experimental animals. Papeschi R; Sourkes TL; Poirier LJ; Boucher R Brain Res; 1971 May; 28(3):527-33. PubMed ID: 5000053 [No Abstract] [Full Text] [Related]
71. Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. Tassorelli C; Armentero MT; Greco R; Fancellu R; Sandrini G; Nappi G; Blandini F Brain Res; 2007 Oct; 1176():53-61. PubMed ID: 17884026 [TBL] [Abstract][Full Text] [Related]
72. The nigrostriatal dopamine system and the development of hypertension in the spontaneously hypertensive rat. de Jong W; Linthorst AC; Versteeg HG Arch Mal Coeur Vaiss; 1995 Aug; 88(8):1193-6. PubMed ID: 8572872 [TBL] [Abstract][Full Text] [Related]
73. Basic research on dopamine in Parkinson's disease and the discovery of the nigrostriatal dopamine pathway: the view of an eyewitness. Hornykiewicz O Neurodegener Dis; 2008; 5(3-4):114-7. PubMed ID: 18322366 [TBL] [Abstract][Full Text] [Related]
74. [Movement disorders and basal ganglia function]. Dietrichs E Tidsskr Nor Laegeforen; 2008 Sep; 128(17):1968-71. PubMed ID: 18787574 [TBL] [Abstract][Full Text] [Related]
75. The influence of group III metabotropic glutamate receptor stimulation by (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid on the parkinsonian-like akinesia and striatal proenkephalin and prodynorphin mRNA expression in rats. Konieczny J; Wardas J; Kuter K; Pilc A; Ossowska K Neuroscience; 2007 Mar; 145(2):611-20. PubMed ID: 17224239 [TBL] [Abstract][Full Text] [Related]
76. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Gaillard A; Decressac M; Frappé I; Fernagut PO; Prestoz L; Besnard S; Jaber M Neurobiol Dis; 2009 Sep; 35(3):477-88. PubMed ID: 19616502 [TBL] [Abstract][Full Text] [Related]
77. [Basis, clinical picture and therapy of diseases of the extrapyramidal-motoric system (EPMS)]. Völler GW; Deze J Z Allgemeinmed; 1975 Mar; 51(8):353-73. PubMed ID: 1094755 [No Abstract] [Full Text] [Related]
78. Distribution and release of GABA in the basal ganglia. Korf J; van der Heyden JA; Venema K; Postema F Adv Biochem Psychopharmacol; 1981; 30():105-17. PubMed ID: 7331934 [No Abstract] [Full Text] [Related]
79. Microdialysis study of the effects of the antiparkinsonian drug budipine on L-DOPA-induced release of dopamine and 5-hydroxytryptamine by rat substantia nigra and corpus striatum. Biggs CS; Starr MS Synapse; 1999 Oct; 34(1):36-46. PubMed ID: 10459170 [TBL] [Abstract][Full Text] [Related]
80. Basic research in substantia nigra and ventral tegmental area: clinical implications. Stratta F; Bonci A; Calabresi P; Stefani A; Pisani A; Bernardi G; Mercuri NB J Neural Transm Suppl; 1995; 45():47-55. PubMed ID: 8748608 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]